MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Heidelberg University · Charité - Universitätsmedizin Berlin · +13 more institutions
Abstract
A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG).
To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack and long-term treatment outcomes.
Citation impact
- FWCI
- 66.23
- Percentile
- 100%
- References
- 129
Authors
31- ICin cooperation with the Neuromyelitis Optica Study Group (NEMOS)Corresponding
Heidelberg University
- SJSven Jarius
Heidelberg University, Charité - Universitätsmedizin Berlin
- KRKlemens Ruprecht
Charité - Universitätsmedizin Berlin, Ruhr University Bochum
- IKIngo Kleiter
Max Delbrück Center, Charité - Universitätsmedizin Berlin, Ruhr University Bochum
- NBNadja Borisow
University of Southern Denmark, Max Delbrück Center, Charité - Universitätsmedizin Berlin
Topics & keywords
- Medicine
- Epidemiology
- Radiological weapon
- Presentation (obstetrics)
- Neurology
- Term (time)
- Pediatrics
- Outcome (game theory)
- Good health and well-being